Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)73.01
  • Today's Change0.600 / 0.83%
  • Shares traded16.00
  • 1 Year change-8.26%
  • Beta0.2008
Data delayed at least 15 minutes, as of Mar 27 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.

  • Revenue in USD (TTM)27.12bn
  • Net income in USD5.66bn
  • Incorporated1987
  • Employees18.00k
  • Location
    Gilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 574-3000
  • Fax+1 (650) 578-9264
  • Websitehttps://www.gilead.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
GILD:NSQ since
announced
Transaction
value
XinThera IncDeal completed09 May 202309 May 2023Deal completed-7.10%--
Data delayed at least 15 minutes, as of Mar 27 2024 20:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Iqvia Holdings Inc14.98bn1.36bn45.84bn87.00k34.617.5018.463.067.307.3080.4233.670.5761--4.76172,229.905.223.246.804.0734.9634.329.066.03--3.240.69110.003.987.5524.4743.397.17--
Zoetis Inc8.54bn2.34bn77.16bn14.10k33.2315.4627.259.035.075.0718.4810.900.5851.036.78605,957.4016.0214.4719.3717.1870.4769.8027.3925.772.0017.150.568226.895.747.9610.8811.1316.7124.37
Gilead Sciences, Inc.27.12bn5.66bn90.95bn18.00k16.213.9810.953.354.504.5021.5618.330.43283.955.751,506,445.008.966.7410.918.1276.0478.6420.6916.951.277.630.523481.22-0.60484.1523.370.7436-8.745.64
Regeneron Pharmaceuticals Inc13.12bn3.95bn106.06bn13.45k27.804.0724.258.0934.7634.76115.32237.410.42110.72892.39975,256.5012.6920.1814.1923.2286.1686.6330.1438.114.94--0.0943--7.7614.34-8.8710.7219.32--
Bristol-Myers Squibb Co45.01bn8.03bn107.68bn34.10k13.803.666.052.393.863.8621.6614.560.46894.245.011,319,824.008.383.0510.893.7676.4476.1317.867.691.3112.390.5743133.63-2.5014.8126.8410.034.927.34
Vertex Pharmaceuticals Incorporated9.87bn3.62bn107.80bn5.40k30.046.1228.3610.9213.8913.8937.8868.220.48282.106.571,827,630.0017.7119.9220.9323.6487.2187.6736.6835.853.78--0.0210.0010.5126.498.9646.5022.02--
Data as of Mar 27 2024. Currency figures normalised to Gilead Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

39.75%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2023106.31m8.53%
Capital Research & Management Co. (World Investors)as of 31 Dec 202383.36m6.69%
BlackRock Fund Advisorsas of 31 Dec 202378.15m6.27%
Capital Research & Management Co. (Global Investors)as of 31 Dec 202359.66m4.79%
SSgA Funds Management, Inc.as of 31 Dec 202359.54m4.78%
Dodge & Coxas of 31 Dec 202333.30m2.67%
Geode Capital Management LLCas of 31 Dec 202325.27m2.03%
Wellington Management Co. LLPas of 31 Dec 202318.63m1.50%
Norges Bank Investment Managementas of 31 Dec 202316.07m1.29%
BlackRock Advisors (UK) Ltd.as of 31 Dec 202314.85m1.19%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.